LY573636-sodium
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sarcoma, Soft Tissue
Conditions
Sarcoma, Soft Tissue
Trial Timeline
Aug 1, 2007 → Feb 1, 2010
NCT ID
NCT00490451About LY573636-sodium
LY573636-sodium is a phase 2 stage product being developed by Eli Lilly for Sarcoma, Soft Tissue. The current trial status is completed. This product is registered under clinical trial identifier NCT00490451. Target conditions include Sarcoma, Soft Tissue.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00992225 | Phase 2 | Completed |
| NCT00718159 | Phase 1 | Completed |
| NCT00490451 | Phase 2 | Completed |
| NCT00428610 | Phase 2 | Completed |
| NCT00363766 | Phase 2 | Completed |
Competing Products
20 competing products in Sarcoma, Soft Tissue